-- ELEVATE-45-201 Cohort 2 (10 mg/kg) enrollment complete with data expected in H1 2027 -- BOSTON, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that an independent safety Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data from the eight participants enrolled in Cohort 2 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of ELEVATE-45-201. The DMC recommended initiating Cohort 3 at the dose of 15 mg/kg, a dose escalation from 10 mg/kg in Cohort 2 and 5 mg/kg in Cohort 1.
Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to a loss of $1.06 per share a year ago.
-- All ELEVATE-44-201 Cohort 1 participants have completed open-label dosing, with data expected to be received by year-end 2026 -- -- Company on track to report ELEVATE-44-201 Cohort 2 data in Q1 2027 – -- ELEVATE-45-201 Cohort 1 data reported in October 2026 met the primary objective of favorable safety and tolerability at an initial dose of 5 mg/kg -- -- ELEVATE-45-201 Cohort 2 enrollment complete and Company on track to report data in H1 2027 -- -- Expected cash runway extended into Q4 2027 with $193 million in cash, cash equivalents and marketable securities as of September 30, 2026 -- BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today reported financial results for the third quarter ended September 30, 2026, and highlighted recent business updates. “The October Cohort 1 data from ELEVATE-45-201 marked our third consecutive readout demonstrating encouraging safety and tolerability across our clinical programs,” said Dipal Doshi, Chief Executive Officer of Entrada Therapeutics.
Entrada Therapeutics (NASDAQ: TRDA - Get Free Report) and X4 Pharmaceuticals (NASDAQ: XFOR - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, earnings and profitability. Insider and Institutional Ownership 86.4% of Entrada
BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Linea Aspesi as Chief People Officer. “Linea has a proven track record of scaling organizations and developing high-performing teams from discovery through commercial stages,” said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics.
-- Company to receive ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data from the eight participants enrolled in Cohort 2 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of ELEVATE-44-201. The DMC recommended initiating Cohort 3 at the top dose of 18 mg/kg, an increase from 12 mg/kg in Cohort 2 and 6 mg/kg in Cohort 1.
-- Cohort 1 met the primary objectives of favorable safety and tolerability at the initial dose of 5 mg/kg -- -- ENTR-601-45 plasma exposures were consistent with those predicted based on juvenile non-human primate exposure data -- -- In line with expectations, the secondary objectives demonstrated a 0.10% mean increase in dystrophin production versus baseline in treated participants at the initial dose of 5 mg/kg -- -- Company expects a significant increase in dystrophin production and functional benefit in future cohorts while maintaining a convenient Q6W dosing schedule -- -- ELEVATE-45-201 Cohort 2 enrollment is complete and the Company is on track to report data at the increased dose of 10 mg/kg in the first half of 2027 -- BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced positive topline data from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of the Phase 1/2 ELEVATE-45-201 clinical study of ENTR-601-45 in ambulatory participants with a confirmed mutation in the DMD gene amenable to exon 45 skipping. Study participants in Cohort 1 received three doses of 5 mg/kg of ENTR-601-45 or placebo.
Entrada Therapeutics is rated Buy with a $8.50 fair value, offering ~52% upside from $5.61, driven by potential validation of its EEV platform. ENTR-601-44's initial dystrophin increase was disappointing, but lower pediatric drug exposure provides a plausible, testable explanation; higher dosing results are expected in Q1 2027. Valuation is anchored by risk-adjusted pipeline estimates and significant cash reserves, with downside to $4–$4.60 if higher dosing fails to deliver.
-- Announced following World Duchenne Awareness Day on September 7, grants are designed to support projects bridging healthcare disparities across the global Duchenne community -- BOSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the recipients of its 2026 DREAMS Grant Program: a competitive annual program that awards two $50,000 grants in support of projects working to better identify, understand and reach members of the Duchenne muscular dystrophy community who are currently underrepresented or underserved.
BlackRock Inc. purchased a new stake in Entrada Therapeutics, Inc. (NASDAQ: TRDA) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 2,583,333 shares of the company's stock, valued at approximately $19,013,000. BlackRock Inc. owned 6.65% of Entrada Therapeutics at